These cytokines are very high in plasma of patients with CKM; therefore, through the reduction of inflammatory signaling, sGC activators help to prevent the downstream effects of chronic inflammation, such as endothelial damage, fibrosis, and organ dysfunction, which are particularly concerning in cancer patients with pre-existing cardiovascular or renal conditions [170]. The gene discussed is SGCB; the disease is cancer.